Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis

Lindsey Kennedy, Heather Francis, Pietro Invernizzi, Julie Venter, Nan Wu, Marco Carbone, M. Eric Gershwin, Francesca Bernuzzi, Antonio Franchitto, Domenico Alvaro, Marco Marzioni, Paolo Onori, Eugenio Gaudio, Amelia Sybenga, Luca Fabris, Fanyin Meng, Shannon Glaser, Gianfranco Alpini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary biliary cholangitis (PBC) primarily targets cholangiocytes and is characterized by liver fibrosis and biliary proliferation. Activation of the secretin (Sct)/secretin receptor (SR) axis, expressed only by cholangiocytes, increases biliary proliferation, liver fibrosis, and bicarbonate secretion. We evaluated the effectiveness of SR antagonist treatment for early-stage PBC. Male and female dominant-negative TGF-β receptor II (dnTGF-βRII) (model of PBC) and wild-type mice at 12 wk of age were treated with saline or the SR antagonist, Sec 5-27, for 1 wk. dnTGF-βRII mice expressed features of early-stage PBC along with enhanced Sct/SR axis activation and Sct secretion. dnTGF-βRII mice had increased biliary proliferation or senescence, inflammation, and liver fibrosis. In dnTGF-βRII mice, there was increased microRNA-125b/TGF-β1/TGF-β receptor 1/VEGF-A signaling. Human early-stage PBC patients had an increase in hepatobiliary Sct and SR expression and serum Sct levels. Increased biliary Sct/SR signaling promotes biliary and hepatic damage during early-stage PBC.-Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Gershwin, M. E., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., Alpini, G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis.

Original languageEnglish (US)
Pages (from-to)10269-10279
Number of pages11
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology
Volume33
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Cholangitis
Secretin
Liver Cirrhosis
Liver
Chemical activation
Bicarbonates
secretin receptor
MicroRNAs
Vascular Endothelial Growth Factor A
Inflammation
Serum

Keywords

  • angiogenesis
  • cellular senescence
  • cholangiopathies
  • liver damage
  • miR-125b

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. / Kennedy, Lindsey; Francis, Heather; Invernizzi, Pietro; Venter, Julie; Wu, Nan; Carbone, Marco; Gershwin, M. Eric; Bernuzzi, Francesca; Franchitto, Antonio; Alvaro, Domenico; Marzioni, Marco; Onori, Paolo; Gaudio, Eugenio; Sybenga, Amelia; Fabris, Luca; Meng, Fanyin; Glaser, Shannon; Alpini, Gianfranco.

In: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 33, No. 9, 01.09.2019, p. 10269-10279.

Research output: Contribution to journalArticle

Kennedy, L, Francis, H, Invernizzi, P, Venter, J, Wu, N, Carbone, M, Gershwin, ME, Bernuzzi, F, Franchitto, A, Alvaro, D, Marzioni, M, Onori, P, Gaudio, E, Sybenga, A, Fabris, L, Meng, F, Glaser, S & Alpini, G 2019, 'Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis', FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol. 33, no. 9, pp. 10269-10279. https://doi.org/10.1096/fj.201802606R
Kennedy, Lindsey ; Francis, Heather ; Invernizzi, Pietro ; Venter, Julie ; Wu, Nan ; Carbone, Marco ; Gershwin, M. Eric ; Bernuzzi, Francesca ; Franchitto, Antonio ; Alvaro, Domenico ; Marzioni, Marco ; Onori, Paolo ; Gaudio, Eugenio ; Sybenga, Amelia ; Fabris, Luca ; Meng, Fanyin ; Glaser, Shannon ; Alpini, Gianfranco. / Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. In: FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019 ; Vol. 33, No. 9. pp. 10269-10279.
@article{e869724bcf464842b155fcb80d847aeb,
title = "Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis",
abstract = "Primary biliary cholangitis (PBC) primarily targets cholangiocytes and is characterized by liver fibrosis and biliary proliferation. Activation of the secretin (Sct)/secretin receptor (SR) axis, expressed only by cholangiocytes, increases biliary proliferation, liver fibrosis, and bicarbonate secretion. We evaluated the effectiveness of SR antagonist treatment for early-stage PBC. Male and female dominant-negative TGF-β receptor II (dnTGF-βRII) (model of PBC) and wild-type mice at 12 wk of age were treated with saline or the SR antagonist, Sec 5-27, for 1 wk. dnTGF-βRII mice expressed features of early-stage PBC along with enhanced Sct/SR axis activation and Sct secretion. dnTGF-βRII mice had increased biliary proliferation or senescence, inflammation, and liver fibrosis. In dnTGF-βRII mice, there was increased microRNA-125b/TGF-β1/TGF-β receptor 1/VEGF-A signaling. Human early-stage PBC patients had an increase in hepatobiliary Sct and SR expression and serum Sct levels. Increased biliary Sct/SR signaling promotes biliary and hepatic damage during early-stage PBC.-Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Gershwin, M. E., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., Alpini, G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis.",
keywords = "angiogenesis, cellular senescence, cholangiopathies, liver damage, miR-125b",
author = "Lindsey Kennedy and Heather Francis and Pietro Invernizzi and Julie Venter and Nan Wu and Marco Carbone and Gershwin, {M. Eric} and Francesca Bernuzzi and Antonio Franchitto and Domenico Alvaro and Marco Marzioni and Paolo Onori and Eugenio Gaudio and Amelia Sybenga and Luca Fabris and Fanyin Meng and Shannon Glaser and Gianfranco Alpini",
year = "2019",
month = "9",
day = "1",
doi = "10.1096/fj.201802606R",
language = "English (US)",
volume = "33",
pages = "10269--10279",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

TY - JOUR

T1 - Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis

AU - Kennedy, Lindsey

AU - Francis, Heather

AU - Invernizzi, Pietro

AU - Venter, Julie

AU - Wu, Nan

AU - Carbone, Marco

AU - Gershwin, M. Eric

AU - Bernuzzi, Francesca

AU - Franchitto, Antonio

AU - Alvaro, Domenico

AU - Marzioni, Marco

AU - Onori, Paolo

AU - Gaudio, Eugenio

AU - Sybenga, Amelia

AU - Fabris, Luca

AU - Meng, Fanyin

AU - Glaser, Shannon

AU - Alpini, Gianfranco

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Primary biliary cholangitis (PBC) primarily targets cholangiocytes and is characterized by liver fibrosis and biliary proliferation. Activation of the secretin (Sct)/secretin receptor (SR) axis, expressed only by cholangiocytes, increases biliary proliferation, liver fibrosis, and bicarbonate secretion. We evaluated the effectiveness of SR antagonist treatment for early-stage PBC. Male and female dominant-negative TGF-β receptor II (dnTGF-βRII) (model of PBC) and wild-type mice at 12 wk of age were treated with saline or the SR antagonist, Sec 5-27, for 1 wk. dnTGF-βRII mice expressed features of early-stage PBC along with enhanced Sct/SR axis activation and Sct secretion. dnTGF-βRII mice had increased biliary proliferation or senescence, inflammation, and liver fibrosis. In dnTGF-βRII mice, there was increased microRNA-125b/TGF-β1/TGF-β receptor 1/VEGF-A signaling. Human early-stage PBC patients had an increase in hepatobiliary Sct and SR expression and serum Sct levels. Increased biliary Sct/SR signaling promotes biliary and hepatic damage during early-stage PBC.-Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Gershwin, M. E., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., Alpini, G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis.

AB - Primary biliary cholangitis (PBC) primarily targets cholangiocytes and is characterized by liver fibrosis and biliary proliferation. Activation of the secretin (Sct)/secretin receptor (SR) axis, expressed only by cholangiocytes, increases biliary proliferation, liver fibrosis, and bicarbonate secretion. We evaluated the effectiveness of SR antagonist treatment for early-stage PBC. Male and female dominant-negative TGF-β receptor II (dnTGF-βRII) (model of PBC) and wild-type mice at 12 wk of age were treated with saline or the SR antagonist, Sec 5-27, for 1 wk. dnTGF-βRII mice expressed features of early-stage PBC along with enhanced Sct/SR axis activation and Sct secretion. dnTGF-βRII mice had increased biliary proliferation or senescence, inflammation, and liver fibrosis. In dnTGF-βRII mice, there was increased microRNA-125b/TGF-β1/TGF-β receptor 1/VEGF-A signaling. Human early-stage PBC patients had an increase in hepatobiliary Sct and SR expression and serum Sct levels. Increased biliary Sct/SR signaling promotes biliary and hepatic damage during early-stage PBC.-Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Gershwin, M. E., Bernuzzi, F., Franchitto, A., Alvaro, D., Marzioni, M., Onori, P., Gaudio, E., Sybenga, A., Fabris, L., Meng, F., Glaser, S., Alpini, G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis.

KW - angiogenesis

KW - cellular senescence

KW - cholangiopathies

KW - liver damage

KW - miR-125b

UR - http://www.scopus.com/inward/record.url?scp=85071788352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071788352&partnerID=8YFLogxK

U2 - 10.1096/fj.201802606R

DO - 10.1096/fj.201802606R

M3 - Article

C2 - 31251081

AN - SCOPUS:85071788352

VL - 33

SP - 10269

EP - 10279

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -